TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Relative Strength Index (RSI) is 60.24, with weekly volatility at 10.20% and ATR at 0.88. The TCON stock’s 52-week price range has touched low of $0.95 and a $10.65 high. Intraday shares traded counted 1.53 million, which was -102.37% lower than its 30-day average trading volume of 758.30K. Its shares traded higher over the last trading session, gaining 10.49% on 12/22/20. The shares fell to a low of $7.83 before closing at $8.95. TCON’s previous close was $8.10 while the outstanding shares total 10.51M. The firm has a beta of 1.96.
Investors have identified the Biotechnology company TRACON Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $121.27 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
TRACON Pharmaceuticals Inc. (TCON) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TCON, the company has in raw cash 26.45 million on their books with 2.46 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 27.45 million total, with 9.95 million as their total liabilities.
Potential earnings growth for TRACON Pharmaceuticals Inc. (TCON)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the Q3 2020 quarter of the year, TRACON Pharmaceuticals Inc. recorded a total of 3.85 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -32.04% coming in sequential stages and their sales for the Q3 2020 quarter reducing by -12.11%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent -3.85 million trying to sell their products during the last quarter, with the result yielding a gross income of 0.14 million. This allows shareholders to hold on to 10.51M with the recently reported earning now reading -0.38 cents per share. This is a figure that compared to analyst’s prediction for their Q3 2020 (-0.38 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.43 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TCON sounds very interesting.
Is the stock of TCON attractive?
In related news, Member of 10% Group, Ikarian Capital, LLC bought 5,000 shares of the company’s stock in a transaction that recorded on Nov 11. The purchase was performed at an average price of 7.53, for a total value of 37,629. As the purchase deal closes, the Member of 10% Group, Ikarian Capital, LLC now bought 21,300 shares of the company’s stock, valued at 98,907. Also, Member of 10% Group, Ikarian Capital, LLC bought 7,700 shares of the company’s stock in a deal that was recorded on Oct 29. The shares were cost at an average price of 4.77 per share, with a total market value of 36,734. Following this completion of disposal, the President and CEO, THEUER CHARLES now holds 2,000 shares of the company’s stock, valued at 8,769. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.50%.
2 out of 4 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on TRACON Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the TCON stock. The 12-month mean consensus price target for the company’s shares has been set at $9.17.